Stock markets climb for 2nd day on buying in IT stocks, Reliance Industries
时间:2024-06-26 15:58:57 阅读(143)
Benchmark equity indices Sensex and Nifty rallied for a second straight session on Monday following buying in index heavyweight IT counters and Reliance Industries amid optimism in Asian markets.
The 30-share BSE Sensex climbed 234 points or 0.38 per cent to settle at 61,963.68. During the day, it jumped 314.78 points or 0.50 per cent to 62,044.46.The NSE Nifty rallied 111 points or 0.61 per cent to end at 18,314.40.Among the Sensex firms, Tech Mahindra, Wipro, Infosys, Tata Consultancy Services, HCL Technologies, Larsen & Toubro, ITC, Sun Pharma, NTPC and Titan were the major gainers.Nestle, Axis Bank, Tata Motors, ICICI Bank, HDFC Bank and Bharti Airtel were the laggards.All the ten listed Adani group stocks ended with significant gains as a Supreme Court-appointed expert committee said it has found no evidence of stock price manipulation in group companies, while a separate Sebi probe into alleged violation in money flows from offshore entities has “drawn a blank”. Adani Enterprises zoomed 18.84 per cent and Adani Wilmar jumped 10 per cent, the biggest gainers among the ten listed group firms.
Meanwhile, global oil benchmark Brent crude climbed 0.03 per cent to USD 75.60 per barrel.The Sensex climbed 297.94 points or 0.48 per cent to settle at 61,729.68 on Friday. The Nifty advanced 73.45 points or 0.41 per cent to end at 18,203.40.Foreign institutional investors (FIIs) offloaded equities worth Rs 113.46 crore on Friday after remaining buyers for a number of days, according to exchange data.
猜你喜欢
- Nifty crashes ahead of Budget 2023; should you buy on dips or cut your positions-
- The war in the Gaza has destroyed the myth of the power of the Israeli army
- Bharat Forge rating – Reduce- Numbers were below expectations
- Tech stocks may fall further, says Chris Wood
- Nifty Jumps above 17760, Sensex surges 600 pts in early trade on Mon, Mar 6; Adani stocks, Bajaj Electricals rise
- Bombay Dyeing shares rise 20% on land deal; debt reduction plans
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- NBCC (India) secures order worth Rs 218 crore from NIFT
- Top-10 most valued firms lose over Rs 2